SYDNEY, March 31, 2025–Novotech, a globally recognized full-service biotech specialist clinical research organization (CRO), announced today that affiliates of GIC and Temasek have signed binding agreements to acquire a significant stake in the company, with the additional capital earmarked to accelerate its global growth. Existing investor TPG will also reinvest through its TPG Asia fund.Read More
Novotech Welcomes New Investment From GIC, Temasek, and Existing Investor TPG to Accelerate Global Growth
